We studied the mechanism of plasma and tissue kallikrein in activating plasminogen.
作者研究了血浆和组织激肽释放酶激活纤溶酶原的机制。
Conclusion It is safe and effective by using urinary kallikrein on acute cerebral infarction.
结论尤瑞克林治疗急性脑梗死安全有效。
Objective:To explore the possibility of the simultaneous extraction of urokinase and kallikrein.
目的：探讨尿激酶及激肽释放酶同时提取的可能性。
It was presumed that KBP may playa role in the regulation of metabolism of tissue kallikrein on the level of biosynthesis and excretion.
推测KBP可能在合成和分泌的水平上，对组织激肽释放酶的代谢及活性起调节作用。
On the cell of expressing human tissue kallikrein for gene modification, rigid envelope material with bi-directional flowability is coated.
在基因修饰的表达人组织激肽释放酶的细胞上包覆着具有刚性和双向流通性的包膜材料；
Aim: To investigate the expression of human kallikrein 15 (KLK15) in the primary epithelial ovarian carcinoma and the clinical significance.
目的：研究上皮性卵巢癌组织中人类组织激肽释放酶15 (KLK15)蛋白的表达。
Therefore, it is possible that renal tissue kallikrein-bradykinin system is also released and activated by the stimulation of inflammation in sepsis.
因此，肾脏的组织型血管增渗酶也有可能被败血症引发的发炎反应刺激而释放出来，并产生作用。
CONCLUSION Human urinary kallikrein is effective and relatively safe in treatment of acute cerebral infarction in the vascular distribution of the internal carotid artery.
结论人尿激肽原酶治疗急性颈内动脉系统脑梗死所致的神经功能缺损，其效果及安全性良好。
The present invention relates to human tissue kallikrein, and is especially the microcapsulized cell of human tissue kallikrein and its microcapsulizing method and application.
本发明涉及人组织激肽释放酶，具体地说是人组织激肽释放酶的微囊化细胞及其微囊化方法和应用；
The invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method.
本发明涉及人尿激肽原酶用于治疗急性冠状动脉疾病的药物用途及按该方法制备的药物组合物。
The invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method.
本发明涉及人尿激肽原酶用于治疗急性冠状动脉疾病的药物用途及按该方法制备的药物组合物。
应用推荐